What is the most recent earnings date for CGEM stock?
CULLINAN THERAPEUTICS INC (CGEM) last reported earnings on 3/10/2026.
NASDAQ:CGEM • US2300311063
Past quarterly earnings results for CULLINAN THERAPEUTICS INC (CGEM), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.77 | -0.83 | 6.74% | -5.48% | - | - | ||
| Q3 2025 | -0.77 | -0.98 | 21.14% | -11.59% | - | - | ||
| Q2 2025 | -1.07 | -0.85 | -25.93% | -42.67% | - | - | ||
| Q1 2025 | -0.74 | -0.82 | 9.46% | 13.95% | - | - | ||
| Q4 2024 | -0.73 | -0.77 | 5.54% | -35.19% | - | - | ||
| Q3 2024 | -0.69 | -0.82 | 16.07% | 24.18% | - | - | ||
| Q2 2024 | -0.75 | -0.74 | -1.34% | 8.54% | - | - | ||
| Q1 2024 | -0.86 | -1.01 | 14.81% | 39.44% | - | - | ||
| Q4 2023 | -0.54 | -0.98 | 44.93% | 8.47% | - | - | ||
| Q3 2023 | -0.91 | -0.94 | 3.20% | -68.52% | - | - | ||
| Q2 2023 | -0.82 | -0.99 | 17.12% | -121.75% | - | - | ||
| Q1 2023 | -1.42 | -1.00 | -42.06% | -425.93% | - | - | ||
| Q4 2022 | -0.59 | -0.68 | 13.02% | 20.27% | - | - | ||
| Q3 2022 | -0.54 | -0.99 | 45.23% | -35.00% | - | - | ||
| Q2 2022 | 3.77 | 5.53 | -31.76% | 1,147.22% | 280.5M | -100.00% | - | |
| Q1 2022 | -0.27 | -0.62 | 56.61% | - | - | -100.00% | ||
| Q4 2021 | -0.74 | -0.48 | -53.27% | 74.13% | - | - | ||
| Q3 2021 | -0.40 | -0.43 | 7.36% | - | - | - | ||
| Q2 2021 | -0.36 | -0.42 | 14.95% | - | - | - | ||
| Q1 2021 | 0.00 | 0.07 | -100.00% | - | 18.94M | 19.38M | -2.27% | - |
| Q4 2020 | -2.86 | -0.39 | -628.29% | - | 9.18M | -100.00% | - | |
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - |
Notes
CULLINAN THERAPEUTICS INC (CGEM) last reported earnings on 3/10/2026.
CULLINAN THERAPEUTICS INC (CGEM) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CULLINAN THERAPEUTICS INC (CGEM) has beaten EPS estimates in 3 out of 4 releases.